Human recombinant alkaline phosphatase inhibits ex vivo platelet activation in humans

Summary

Sepsis-associated acute kidney injury (AKI) is associated with high morbidity and mortality. Excessive platelet activation contributes to AKI through the formation of microthrombi and amplification of systemic inflammation. Two phase II trials demonstrated that bovine-intestinal alkaline phosphatase (AP) improved renal function in critically ill patients with sepsis-associated AKI. In this study, we characterised the platelet-inhibiting effects of a human recombinant AP. Whole blood and platelet-rich plasma (PRP) of healthy volunteers (n=6) was pre-treated ex vivo with recAP, whereafter platelet reactivity to ADP, collagen-related peptide (CRP-XL) and Pam3CSK4 was determined by flow cytometry. RecAP (40 U/ml) reduced the platelet reactivity to ADP (inhibition with a median of 47%, interquartile range 43–49%; p<0.001) and tended to reduce platelet reactivity to CRP-XL (9%, 2–25%; p=0.08) in whole blood. The platelet-inhibiting effects of recAP were more pronounced in PRP both for ADP- (64%, 54–68%; p=0.002) and CRP-XL-stimulated samples (60%, 46–71%; p=0.002). RecAP rapidly converted ADP into adenosine, whereas antagonism of the A2A adenosine receptor partially reversed the platelet inhibitory effects of recAP. Platelets of septic shock patients (n=5) showed a 31% (22–34%; p=0.03) more pronounced reactivity compared to healthy volunteers, and this was completely reversed by recAP treatment. In conclusion, we demonstrate that recAP inhibits ex vivo human platelet activation through dephosphorylation of ADP and formation of adenosine as its turnover product. RecAP is able to reverse the platelet hyperreactivity present in septic shock patients. These effects may contribute to the beneficial effects of recAP as a new therapeutic candidate for sepsis-associated AKI.

Keywords

Platelet activation - antiplatelet agents - sepsis - acute kidney injury - alkaline phosphatase

• References

• 1 Stevenson EK, Rubenstein AR, Radin GT. et al. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis*. Cri Care Med 2014; 42: 625-631.
• 2 Goldberg R, Dennen P. Long-term outcomes of acute kidney injury. Adv Chron Kidney Dis 2008; 15: 297-307.
• 3 Case J, Khan S, Khalid R. et al. Epidemiology of Acute Kidney Injury in the Intensive Care Unit. Crit Care Res Pract 2013; 2013: 9.
• 4 Millán JL. Alkaline Phosphatases: Structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. Purinergic Signal 2006; 02: 335-341.
• 5 Heemskerk S, Masereeuw R, Moesker O. et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med 2009; 37: 417-423 e1.
• 6 Pickkers P, Heemskerk S, Schouten J. et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care 2012; 16: R14.
• 7 Kiffer-Moreira T, Sheen CR, da Silva Gasque KC. et al. Catalytic signature of a heat-stable, chimeric human alkaline phosphatase with therapeutic potential. PloS one 2014; 09: e89374.
• 8 Bentala H, Verweij WR, Huizinga-der Vlag A. et al. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 2002; 18: 561-566.
• 9 Bours MJ, Swennen EL, Di Virgilio F. et al. Adenosine 5’-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 2006; 112: 358-404.
• 10 Peters E, Geraci S, Heemskerk S. et al. Alkaline phosphatase protects against renal inflammation through dephosphorylation of lipopolysaccharide and ade-nosine triphosphate. Br J Pharmacol 2015 Epub ahead of print.
• 11 Dorsam RT, Kunapuli SP. Central role of the P2Y(12) receptor in platelet activation. J Clin Invest 2004; 113: 340-345.
• 12 Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010; 09: 154-169.
• 13 Haslam RJ, Rosson GM. Effects of adenosine on levels of adenosine cyclic 3’, 5’-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol Pharmacol 1975; 11: 528-544.
• 14 Weitberg AB. The effect of alkaline phosphatase on platelet aggregation. Haematologia 1989; 22: 65-68.
• 15 Hatmi M, Haye B, Gavaret JM. et al. Alkaline phosphatase prevents platelet stimulation by thromboxane mimetics. Br J Pharmacol 1991; 104: 554-558.
• 16 Margolin N, True TA, Saussy Jr. DL. et al. Effect of alkaline phosphatase on thromboxane mimetic induced platelet activation. Prostaglandins 1994; 48: 235-246.
• 17 Semeraro N, Ammollo CT, Semeraro F. et al. Sepsis, thrombosis and organ dysfunction. Thromb Res 2012; 129: 290-295.
• 18 Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost 2013 2013.
• 19 Mavrommatis AC, Theodoridis T, Orfanidou A. et al. Coagulation system and platelets are fully activated in uncomplicated sepsis. Cri Care Med 2000; 28: 451-457.
• 20 van Bladel ER, de Jager RL, Walter D. et al. Platelets of patients with chronic kidney disease demonstrate deficient platelet reactivity in vitro. BMC Nephrol 2012; 13: 127.
• 21 Tunjungputri RN, Van Der Ven AJ, Schonsberg A. et al. Reduced platelet hyperreactivity and platelet-monocyte aggregation in HIV-infected individuals receiving a raltegravir-based regimen. AIDS 2014; 28: 2091-2096.
• 22 Michelson AD, Barnard MR, Krueger LA. et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-1537.
• 23 Rondina MT, Weyrich AS, Zimmerman GA. Platelets as cellular effectors of inflammation in vascular diseases. Circulation Res 2013; 112: 1506-1519.
• 24 American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
• 25 Handa M, Guidotti G. Purification and cloning of a soluble ATP-diphosphohydrolase (apyrase) from potato tubers (Solanum tuberosum). Biochem Biophys Res Commun 1996; 218: 916-923.
• 26 Marcus AJ, Broekman MJ, Drosopoulos JH. et al. The endothelial cell ecto-AD-Pase responsible for inhibition of platelet function is CD39. J Clin Invest 1997; 99: 1351-1360.
• 27 Yang D, Chen H, Koupenova M. et al. A new role for the A2b adenosine receptor in regulating platelet function. J Thromb Haemost 2010; 08: 817-827.
• 28 Peters E, Mehta RL, Murray PT. et al. Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI). BMJ Open 2016; 06: e012371.
• 29 Hechler B, Léon C, Vial C. et al. The P2Y1 Receptor Is Necessary for Adenosine 5’-Diphosphate-Induced Platelet Aggregation. Blood 1998; 92: 152-159.
• 30 Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor?. Blood 2003; 102: 449-461.
• 31 Blair P, Rex S, Vitseva O. et al. Stimulation of Toll-Like Receptor 2 in Human Platelets Induces a Thromboinflammatory Response Through Activation of Phosphoinositide 3-Kinase. Circulation Res 2009; 104: 346-354.
• 32 Klarstrom Engstrom K, Brommesson C, Kalvegren H. et al. Toll like receptor 2/1 mediated platelet adhesion and activation on bacterial mimetic surfaces is dependent on src/Syk-signaling and purinergic receptor P2×1 and P2Y12 activation. Biointerphases 2014; 09: 041003.
• 33 Altieri D, Edgington T. The saturable high affinity association of factor X to ADP-stimulated monocytes defines a novel function of the Mac-1 receptor. J Biol Chem 1988; 263: 7007-7015.
• 34 Wang L, Jacobsen SE, Bengtsson A. et al. P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol 2004; 05: 16.
• 35 Sluyter R. P2X and P2Y receptor signaling in red blood cells. Front Mol Biosci 2015 Epub ahead of print.
• 36 Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic Signaling during Inflammation. N Engl J Med 2012; 367: 2322-2333.
• 37 Johnston Cox HA, Yang D, Ravid K. Physiological implications of adenosine receptor mediated platelet aggregation. J Cell Physiol 2011; 226: 46-51.
• 38 de Stoppelaar SF, van ’t Veer C, van der Poll T. The role of platelets in sepsis. Thromb Haemost 2014; 112: 666-677.
• 39 Singbartl K, Ley K. Leukocyte recruitment and acute renal failure. J Mol Med 2004; 82: 91-101.
• 40 Singbartl K, Forlow SB, Ley K. Platelet, but not endothelial, P-selectin is critical for neutrophil-mediated acute postischemic renal failure. FASEB J 2001; 15: 2337-2344.
• 41 Beumer C, Wulferink M, Raaben W. et al. Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. J Pharmacol Exp Therap 2003; 307: 737-744.
• 42 Tunjungputri R, van der Ven A, Riksen N. et al. Differential effects of platelets and platelet inhibition by ticagrelor on TLR2-and TLR4-mediated inflammatory responses. Thromb Haemost 2015; 113: 1035-1045.
• 43 Montrucchio G, Bosco O, Del Sorbo L. et al. Mechanisms of the priming effect of low doses of lipopoly-saccharides on leukocyte-dependent platelet aggregation in whole blood. Thromb Haemost 2003; 90: 872-881.
• 44 Boldt J, Muller M, Heesen M. et al. Influence of different volume therapies on platelet function in the critically ill. Inten Care Med 1996; 22: 1075-1081.
• 45 Yaguchi A, Lobo F, Vincent JL. et al. Platelet function in sepsis. J Thromb Haemost 2004; 02: 2096-2102.
• 46 Woth G, Varga A, Ghosh S. et al. Platelet aggregation in severe sepsis. J Thromb Thromb 2011; 31: 6-12.
• 47 Gawaz M, Fateh-Moghadam S, Pilz G. et al. Platelet activation and interaction with leucocytes in patients with sepsis or multiple organ failure. Eur J Clin Invest 1995; 25: 843-851.
• 48 Russwurm S, Vickers J, Meier-Hellmann A. et al. Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock 2002; 17: 263-268.
• 49 de Stoppelaar SF, Van’t Veer C, van den Boogaard FE. et al. Protease activated receptor 4 limits bacterial growth and lung pathology during late stage Streptococcus pneumoniae induced pneumonia in mice. Thromb Haemost 2013; 110: 582-592.
• 50 Picker SM. In-vitro assessment of platelet function. Transfusion Apheresis Sci 2011; 44: 305-319.
• 51 Stafford NP, Pink AE, White AE. et al. Mechanisms involved in adenosine triphosphate--induced platelet aggregation in whole blood. Arterioscler Thromb Vasc Biol 2003; 23: 1928-1933.
• 52 Glenn JR, White AE, Johnson A. et al. Leukocyte count and leukocyte ecto-nucleotidase are major determinants of the effects of adenosine triphosphate and adenosine diphosphate on platelet aggregation in human blood. Platelets 2005; 16: 159-170.
• 53 Thomas MR, Storey RF. Effect of P2Y12 inhibitors on inflammation and immunity. Thromb Haemost 2015; 114: 490-497.
• 54 Winning J, Neumann J, Kohl M. et al. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit*. Crit Care Med 2010; 38: 32-37.
• 55 Winning J, Reichel J, Eisenhut Y. et al. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets 2009; 20: 50-57.
• 56 Valerio-Rojas JC, Jaffer IJ, Kor DJ. et al. Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: a historical cohort study. Crit Care Res Pract 2013; 2013: 782573.
• 57 Sossdorf M, Otto GP, Boettel J. et al. Benefit of low-dose aspirin and non-steroidal anti-inflammatory drugs in septic patients. Crit Care 2013; 17: 1-2.
• 58 Otto GP, Sossdorf M, Boettel J. et al. Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock. Platelets 2013; 24: 480-485.
• 59 Gross AK, Dunn SP, Feola DJ. et al. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thromb 2013; 35: 147-154.
• 60 Xiao Z, Théroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004; 43: 1982-1988.
• 61 Nylander S, Femia EA, Scavone M. et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost 2013; 11: 1867-1876.